Elle Lilly allocates $750M for US pharma expansion
Eli Lilly announces a investment of $750 million to expand pharmaceutical manufacturing capabilities in the United States, aims to strengthen the local supply chain and increase biopharmaceutical production. The investment seeks to create 400 high-skilled jobs in the Cincinnati area, and includes the production of products such as the "Quick Pen" insulin pen for diabetes and obesity treatment. Since partnering with Resilient in 2023, the company has produced over 150 million doses for patients in the U.S., as part of efforts to meet the rising demand and address potential import tariffs on medications. Since 2020, Eli Lilly's investments have exceeded $55 billion in expanding U.S. manufacturing facilities.
Notice: This Is an AI-Generated Summary
Comments (0)